IMRT Safety the Focus of New ASTRO Report
The report broadly addresses safe delivery of IMRT, with a primary focus on recommendations for human error prevention and methods to reduce the occurrence of errors or machine malfunctions that can lead to errors or “catastrophic failures,” ASTRO officials said.
American Society for Radiation Oncology (ASTRO) has published the first of its reports on improving safety in radiation oncology. The paper, “Safety Considerations for IMRT,” was published online this month in the ASTRO journal, Practical Radiation Oncology. Jean Moran, PhD, of the University of Michigan in Ann Arbor, was lead author.
The focuses on the safety of intensity modulated radiation therapy and was commissioned in January 2010, following New York Times reports on serious accidents involving IMRT and other types of radiation treatment.
The report broadly addresses safe delivery of IMRT, with a primary focus on recommendations for human error prevention and methods to reduce the occurrence of errors or machine malfunctions that can lead to errors or “catastrophic failures,” ASTRO officials said.
Among other issues, the report touches up on elements of a “culture of safety” (mutual trust, defined roles and responsibilities, event tracking); technical considerations (training, IMRT system commissioning, QA program); and includes a list of recommendations to safeguard against catastrophic failures in IMRT.
The report suggests use of a “forced time out” to assure adequate time to perform reviews and quality assurance at key points in the process.
“Team members need to acknowledge that initiation of treatment may need to be delayed to allow time for necessary QA checks and subsequent investigations of problems,” the authors said.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
